Method for reversing function of N2-type neutrophil and function-reversed N2-type neutrophil based on method

By adding bile acids to N2-type neutrophils, changing their metabolism mode, reversing their function, and making them approach N1, the problem of inhibiting T cells and NK cells in the tumor microenvironment is solved, and the tumor is achieved Effective inhibition and immune activation.

CN119020285APending Publication Date: 2024-11-26HUAZHONG UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310615425.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-24
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art has failed to effectively reverse the function of N2 neutrophils, resulting in its inhibition of T cell and NK cell functions in the tumor microenvironment, promoting tumor progression, and lacking effective anti-tumor immunity methods.

Method used

By adding bile acids to N2 neutrophils, it changes its metabolism method, reduces its ability to secrete immunosuppressive factors, enhances its ability to secrete immune promoters, and weakens the inhibitory effect on lymphocyte proliferation, thereby reversing its function and making it more tempting Nearly N1 type neutrophils.

Benefits of technology

Successfully reversed the function of N2 neutrophils, activate anti-tumor immunity, inhibit tumor growth, significantly reduced tumor size, improved proliferation activity against CD8+ T cells, and showed effectiveness in mouse melanoma and colon cancer models anti-tumor effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020285A_ABST
    Figure CN119020285A_ABST
Patent Text Reader

Abstract

The invention relates to a method for reversing the function of N2-type neutrophil and the N2-type neutrophil with the reversed function based on the method. The invention firstly provides a method for reversing the function of N2-type neutrophils. The method comprises the step of adding bile acid into the N2-type neutrophils. The bile acid is added into the growth environment of the N2 type neutrophil, so that the ability of the N2 type neutrophil to secrete cytokines and the like is effectively reversed, and the N2 type neutrophil approaches to the N1 type neutrophil. Meanwhile, the proliferation inhibition effect of the N2 type neutrophil regulated by bile acid metabolism on lymphocytes such as CD8 + T cells disappears, so that the anti-tumor immunity can be activated through the interaction between immune cells, and the anti-tumor effect is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a method for reversing the function of N2 neutrophils and N2 neutrophils with reversed function based on the method. Background Art

[0002] Neutrophils are the largest group of white blood cells in the body, accounting for about 50% to 70% of the total white blood cells in the body. 11 Neutrophils are produced and play an immune surveillance function in the peripheral circulatory system, clearing foreign microorganisms that invade the body and maintaining the body's immune homeostasis.

[0003] In the tumor microenvironment, neutrophils are divided into N1 neutrophils and N2 neutrophils. Different neutrophil subsets play a double-edged sword role. On the one hand, neutrophils can play an anti-tumor role by upregulating the expression levels of proteins such as nitric oxide synthase 2 (NOS2), NADP oxidase 2 (nicotinamide adenine dinucleotidephosphate oxidase 2, NOX2), and interferon-γ (IFN-γ). On the other hand, during the development of the tumor, the number of N2 neutrophils continues to increase. N2 neutrophils secrete molecules such as interleukin 10 (IL-10), transforming growth factor β (TGF-β), and arginase, which inhibit the function of T cells and NK cells and promote tumor progression.

[0004] Current tumor immunotherapy methods have various problems. For example, the response rate of blocking antibodies such as PD-1 / PD-L1 is limited and recurrence is prone to occur; CAR-T cell therapy has limited effect in the treatment of solid tumors; autologous CAR-NKT therapy shows strong toxicity, and a clinical trial targeting GD2 was suspended by the US FDA due to patient deaths. Neutrophils are a large group present in the tumor microenvironment. How to exert the anti-tumor effect of neutrophils instead of promoting tumor growth has become an important issue to be solved. Therefore, how to reverse the function of N2 neutrophils, downregulate their immunosuppressive molecules, and relieve their immunosuppressive effects on T cells, etc., is of great significance for anti-tumor immunity. Summary of the invention

[0005] Problem that the invention aims to solve

[0006] The existing technology has gradually deepened the research on N1 neutrophils and N2 neutrophils, but there is still no effective method for reversing the function of neutrophils. In this regard, based on the principle that changes in metabolic patterns play an important role in the functional transformation of immune cells, the present invention intends to achieve the purpose of reversing the function of N2 neutrophils through metabolic regulation.

[0007] Solutions for solving problems

[0008] A first aspect of the present invention provides a method for reversing the function of N2 neutrophils, the method comprising the step of adding bile acid to N2 neutrophils.

[0009] In some embodiments, the bile acid comprises one or more of chenodeoxycholic acid, cholic acid, deoxycholic acid, lithocholic acid, and 6-ethylchenodeoxycholic acid.

[0010] In some embodiments, before the step of adding bile acid to N2 neutrophils, the method further comprises the step of inducing N2 neutrophils in vitro.

[0011] In some embodiments, in the step of adding bile acid to the N2 neutrophils, the amount of bile acid added is such that the growth environment of the N2 neutrophils contains 40-60 μM bile acid.

[0012] In some specific embodiments, the step of adding bile acid to N2 neutrophils comprises adding bile acid to N2 neutrophils induced in vitro, or delivering bile acid to an individual containing N2 neutrophils. In some embodiments, the delivery comprises oral administration.

[0013] In some embodiments, the reversal of the function of N2 neutrophils comprises any one or more of the following (i) to (iii):

[0014] (i) Reduce or eliminate the ability of N2 neutrophils to secrete immunosuppressive factors;

[0015] (ii) enabling N2 neutrophils to produce or enhance their ability to secrete immune-promoting factors;

[0016] (iii) Reduce or eliminate the ability of N2 neutrophils to inhibit lymphocyte proliferation.

[0017] In some specific embodiments, the immunosuppressive factors include one or more of IL-10, TGF-β and arginase, the immunopromoting factors include one or more of NOS2, NOX2 and IFN-γ, and the lymphocytes include T cells and NK cells.

[0018] The second aspect of the present invention provides a function-reversed N2 neutrophil, which is prepared by the method described in the first aspect of the present invention.

[0019] In some embodiments, the functions of the functionally reversed N2 neutrophils include any one or more of the following (i) to (iii):

[0020] (i) reduced or absent ability to secrete immunosuppressive molecules;

[0021] (ii) the ability to produce or enhance the secretion of immune-promoting factors;

[0022] (iii) Reduced or absent ability to inhibit lymphocyte proliferation.

[0023] In some specific embodiments, the immunosuppressive factors include one or more of IL-10, TGF-β and arginase, the immunopromoting factors include one or more of NOS2, NOX2 and IFN-γ, and the lymphocytes include T cells and NK cells.

[0024] The third aspect of the present invention provides use of the functionally reversed N2 neutrophils described in the second aspect of the present invention in the preparation of a drug for preventing and / or treating tumors;

[0025] In some specific embodiments, the tumor includes any one or more of liver cancer, lung cancer, pancreatic cancer, kidney cancer, gastric cancer, esophageal cancer, colon cancer, bladder cancer, breast cancer, ovarian cancer, cervical cancer, renal clear cell carcinoma, melanoma, fibroma and nasopharyngeal carcinoma.

[0026] A fourth aspect of the present invention provides a method for preventing and / or treating tumors, the method comprising the step of reversing the function of N2 neutrophils.

[0027] In some specific embodiments, the method comprises the step of administering the function-reversed N2 neutrophils described in the second aspect of the present invention to an individual in need thereof.

[0028] In other specific embodiments, the method comprises the step of administering to an individual in need thereof a bile acid, wherein the bile acid reverses the function of N2 neutrophils in the individual.

[0029] In some specific embodiments, the tumor includes any one or more of liver cancer, lung cancer, pancreatic cancer, kidney cancer, gastric cancer, esophageal cancer, colon cancer, bladder cancer, breast cancer, ovarian cancer, cervical cancer, renal clear cell carcinoma, melanoma, fibroma and nasopharyngeal carcinoma.

[0030] Effects of the Invention

[0031] The present invention first provides a method for reversing the function of N2 neutrophils, by adding bile acid to the growth environment of N2 neutrophils, so that their ability to secrete cytokines and the like is effectively reversed, making N2 neutrophils closer to N1 neutrophils. At the same time, N2 neutrophils regulated by bile acid metabolism have an effect on, for example, CD8 + The proliferation inhibition of lymphocytes such as T cells disappears, and then the anti-tumor immunity can be activated through the interaction between immune cells to play an anti-tumor effect. And the experimental data showed that in the mouse melanoma model and mouse colon cancer model, the tumors of mice after bile acid administration were significantly smaller than those of the control group, proving that bile acid can effectively inhibit the development of tumors by reversing the function of N2 neutrophils. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 The results of flow cytometry analysis of N2 neutrophils isolated from the spleen of tumor-bearing mice after treatment with various bile acids in vitro for 48 hours show that N1 neutrophils (Ly6c + 6G + ) ratio increased significantly.

[0033] Figure 2 Primary cells were isolated from the bone marrow of C57BL / 6J mice, and 20ng / ml of cytokines GM-CSF and IL-6 were added to induce N2 neutrophils in vitro on the fourth day. It was shown that when CDCA was added on the fourth day for 24h or 48h, the expression level of Arg1 gene was reduced and the expression level of NOS2 gene was significantly increased compared with the control group.

[0034] Figure 3 Primary cells were isolated from the bone marrow of C57BL / 6J mice, and 20ng / ml cytokines GM-CSF and IL-6 were added to induce N2 neutrophils in vitro on the fourth day. It was shown that after adding CDCA for 48h on the fourth day, the expression level of Arg1 protein decreased and the expression level of NOS2 protein increased significantly compared with the control group.

[0035] Figure 4 To isolate T cells from mouse spleen, CFSE labeling and staining were performed at 37°C and neutralized after 15 minutes. N2 neutrophils treated with CDCA for 48 hours were co-incubated with T cells, and an appropriate amount of CD3 / CD28 activated magnetic beads were added for stimulation. The proliferation level of T cells was detected after 48 hours, showing that the immunosuppressive effect of N2 neutrophils on T cells was relieved.

[0036] Figure 5C57BL / 6J mice were subcutaneously loaded with B16 tumors and CDCA (20 mg / kg) was administered in drinking water starting on the 10th day of tumor bearing. 3 The mice were sacrificed and the tumors were removed, showing the inhibitory effect of CDCA addition on tumor growth after administration.

[0037] Figure 6 C57BL / 6J mice were subcutaneously loaded with B16 tumors and CDCA (20 mg / kg) was administered in drinking water starting on the 10th day of tumor bearing. 3 The mice were killed and the tumors were removed, showing that the addition of CDCA after administration increased the number and proportion of N1 neutrophils in the tumor microenvironment.

[0038] Figure 7 C57BL / 6J mice were subcutaneously loaded with B16 tumors and CDCA (20 mg / kg) was administered in drinking water starting on the 10th day of tumor bearing. 3 Mice were sacrificed and tumors were removed, showing that the addition of CDCA after administration increased the number and proportion of cytotoxic T cells in the tumor microenvironment.

[0039] Figure 8 C57BL / 6J mice were subcutaneously loaded with MC38 tumors. CDCA, DCA, and OCA (20 mg / kg) were administered to the drinking water on the 10th day of tumor loading. When the tumor size exceeded 2000 mm 3 The mice were killed and the tumors were removed, which showed that the growth of the tumor was controlled to a certain extent after administration. DETAILED DESCRIPTION

[0040] The following describes the embodiments of the present invention, but the present invention is not limited thereto. The present invention is not limited to the various structures described below, and various changes can be made within the scope of the invention claim, and the embodiments and examples obtained by appropriately combining the technical means disclosed in different embodiments and examples are also included in the technical scope of the present invention.

[0041] In the present invention, a numerical range expressed using “a numerical value A to a numerical value B” or “a numerical value A-a numerical value B” means a range including the endpoints A and B.

[0042] In the present invention, a numerical range expressed using "above" or "below" means a numerical range including the number.

[0043] In the present invention, the meaning of "may" includes both the meaning of performing a certain process and the meaning of not performing a certain process. In this specification, "optional" or "optionally" means that the event or situation described below may or may not occur, and the description includes the situation where the event occurs and the situation where the event does not occur.

[0044] In the present invention, the term "a" or "an" or "the" may mean "one", and may also mean "one or more", "at least one" and "one or more than one".

[0045] In the present invention, the terms "comprising", "having", "including" or "containing" may mean inclusive or open-ended, and do not exclude additional, uncited elements or method steps. At the same time, "comprising", "having", "including" or "containing" may also mean closed, excluding additional, uncited elements or method steps.

[0046] In the present invention, the term "about" may mean that a value includes the standard deviation of the error of the device or method used to determine the value. The numerical ranges and parameters used to define the present invention are all approximate values, and the relevant values ​​in the specific embodiments have been presented as accurately as possible. However, any numerical value essentially inevitably contains standard deviations caused by the aforementioned test devices or methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, quantities, values ​​and percentages used in the present invention are modified by "about". Here, "about" generally means that the actual value is within ±10%, ±5%, ±1% or ±0.5% of a particular value or range.

[0047] In the present invention, the term "neutrophil" is also called neutrophil, which is derived from the bone marrow, has a lobed or rod-shaped nucleus, and contains a large number of neutrophil fine particles that are neither basophilic nor eosinophilic in the cytoplasm. In the tumor microenvironment, neutrophils are divided into N1 type and N2 type. In the early stage of tumor occurrence, the neutrophil type is mainly N1 type. N1 type neutrophils have anti-tumor function by secreting type I interferon and IL-18 that activates NK cells. In the process of tumor development, N2 type neutrophils continue to increase. N2 type neutrophils secrete molecules such as IL-10, arginase and TGF-β, inhibit the function of T cells and NK cells, and achieve the effect of promoting tumors.

[0048] In the present invention, the term "bile acid" includes bile acids naturally present in animals, and also includes bile acid mimetics such as bile acid derivatives. In some specific embodiments, the bile acid of the present invention includes one or more of cholic acid (CA), chenodeoxycholic acid (CDCA), deoxycholic acid (DCA), lithochalic acid (LCA) and 6-ethylchenodeoxycholic acid (also known as obeticholic acid, OCA).

[0049] In the present invention, the term "chenodeoxycholic acid" (CDCA) is also called chenodeoxycholic acid, which is a type of bile acid. In the classical human bile acid metabolism pathway, cholesterol is catalyzed by cholesterol-7α-hydroxylase (CYP7A1) to generate 7α-hydroxycholesterol, which is further catalyzed to generate cholic acid (CA) and chenodeoxycholic acid (CDCA).

[0050] In the present invention, the term "functional reversal" or "reversal of function" means that the original function of the cell has changed in the opposite direction, and this change can be a weak change or a strong change, or even a complete change, such as an appropriate change in the original function of the cell, or the cell has a function that it did not originally have, or the original function of the cell disappears. In some typical embodiments, N2 type neutrophils originally have no or weaker ability to secrete immune promoting factors and stronger ability to secrete immune suppressive factors. After appropriate treatment (such as bile acid metabolism regulation), N2 type neutrophils have or have enhanced ability to secrete immune promoting factors and weaker or disappeared ability to secrete immune suppressive factors. In other typical embodiments, N2 type neutrophils originally have the function of inhibiting the proliferation of lymphocytes such as T cells and NK cells. After appropriate treatment (such as bile acid metabolism regulation), the original function of N2 type neutrophils to inhibit the proliferation of lymphocytes such as T cells and NK cells is reduced or disappears.

[0051] In the present invention, the term "immunosuppressive factor" refers to a cytokine that has the function of suppressing immune response, for example, the immunosuppressive factor can transform the phenotype and function of immune cells, weaken their original immune function, and thus promote the development of the disease. In some embodiments, the immunosuppressive factor of the present invention includes one or more of IL-10, TGF-β and arginase.

[0052] In the present invention, the term "immune promoting factor" refers to a cytokine that has the function of promoting immune response, for example, the immune promoting factor can promote the proliferation of immune cells or enhance the toxicity of immune cells, thereby inhibiting the development of diseases. In some embodiments, the immune promoting factor of the present invention includes one or more of NOS2, NOX2 and IFN-γ.

[0053] Unless otherwise defined, other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0054] The present invention is mainly based on the following technical research of the inventor:

[0055] The bile acid metabolism pathway of N1 neutrophils is active, and the content of the product chenodeoxycholic acid (CDCA) is significantly higher than that of N2 neutrophils. Therefore, the present invention first induces N2 neutrophils in vitro, and after successful induction, CDCA is added. The results of qPCR and WB show that the function of the CDCA-treated group is reversed compared with the untreated group, approaching that of N1 neutrophils. Experiments such as CFSE staining also show that the treated group has a negative effect on CD8 + The proliferation inhibition of T cells is released. In addition, animal experiments have verified that reversing the function of N2 neutrophils plays an important role in tumor treatment.

[0056] Example

[0057] The embodiments of the present invention will be described in detail below in conjunction with examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out under normal conditions or conditions recommended by the manufacturer. Unless otherwise specified, the materials or instruments used are all commercially available conventional products.

[0058] The following are various cells, drugs, experimental animals and instruments used in the examples:

[0059] Cells: B16 mouse melanoma cells can be purchased from ATCC in the United States or China Type Culture Collection Center CCTCC; N1 and N2 neutrophils induced and cultured in vitro are obtained by adding interleukin 6 (IL-6) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to primary mouse bone marrow cells. N1 and N2 neutrophils isolated in vivo are isolated from tumors, spleens or bone marrow of tumor-bearing C57 mice.

[0060] Experimental animals: C57BL / 6J mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0061] Instruments and equipment: ACEA NovoCyte series flow cytometer, Bio-Rad PCR instrument, Bio-Rad protein electrophoresis instrument.

[0062] Example 1: Bile acids reverse the N2 neutrophil phenotype to the N1 type

[0063] Experimental materials and reagents:

[0064] C57BL / 6J tumor-bearing mice (B16 melanoma), obeticholic acid (Ocaliva, OCA) (MCE), CDCA, DCA, LCA, CA (sigma), Biolegend CD11b + Biotin-labeled binding antibody, Ly6G, Ly6c flow cytometry antibodies, Miltenyi anti-biotin magnetic beads, Miltenyi magnetic field, percoll separation solution (Biosharp).

[0065] Experimental steps:

[0066] 1. C57BL / 6J mice were subcutaneously loaded with B16 tumors. The mice were killed on the 21st day of tumor bearing and the spleen was isolated from the mice. The spleen tissue was ground and filtered through gauze to prepare a single cell suspension, which was then lysed.

[0067] 2. Obtain the cell suspension after lysis and add 5 μL CD11b + The biotin-labeled antibody was incubated at 4°C for 20 min. Then, an appropriate amount of Miltenyi anti-biotin magnetic beads were added to the antibody-incubated cells and incubated at 4°C in the dark for 20 min. The cells were magnetically sorted in the Miltenyi magnetic field to obtain CD11b + of cells.

[0068] 3. Dilute 100% percoll in the ratio of 80%, 60%, and 50%, and add 2 ml to a 15 ml centrifuge tube starting from 80% concentration, and add the cell suspension of spleen tissue on the top layer.

[0069] Centrifuge at 2500 rpm for 25 min at the lowest acceleration and deceleration speed to collect high-density and low-density cells, which are N1 and N2 neutrophils, respectively.

[0070] 4. N2 neutrophils were cultured in vitro with 20 ng / ml GM-CSF, and 50 μM bile acids (including CDCA, DCA, LCA, CA and OCA) were added for 48 h. N2 neutrophils not treated with bile acids served as the control group.

[0071] 5. After the culture is completed, the cells are collected and stained with surface antibodies on ice in the dark for 30 minutes, followed by flow cytometry detection.

[0072] Experimental results:

[0073] The experimental results are as follows Figure 1 As shown in the figure, the phenotype of N2 neutrophils was reversed after treatment with various bile acids, and the phenotype of N1 neutrophils (Ly6c + 6G + ) ratio increased significantly.

[0074] Example 2: From the genetic level, bile acid CDCA reverses the function of N2 neutrophils

[0075] Experimental materials and reagents:

[0076] C57BL / 6J mice; CDCA (sigma); Bio-Rad SYBR mix; Gibco DMEM medium, Thermo Fisher Trizol extraction reagent.

[0077] Experimental steps:

[0078] 1. Isolate primary bone marrow cells from healthy C57BL / 6J mice, prepare single cell suspension through filtration, add 20ng / ml cytokines GM-CSF and IL-6 for culture after red cell lysis, supplement cytokines and change medium on the 2nd and 4th days.

[0079] 2. On the 4th day, 50 μM CDCA was added and treated for 24 h and 48 h respectively; cells not treated with CDCA served as the control group.

[0080] 3. After processing, collect samples, add Trizol reagent to extract RNA, and perform reverse transcription and qPCR.

[0081] Experimental results:

[0082] The experimental results are as follows Figure 2 As shown, at the gene level, the function of N2 neutrophils was reversed after CDCA treatment. Compared with the control group, the expression level of Arg1 gene was reduced, and the expression level of NOS2 gene was significantly increased; and the result was more significant under 48h treatment time.

[0083] Example 3: Bile acid CDCA reverses N2 neutrophil function at the protein level

[0084] Experimental materials and reagents:

[0085] C57BL / 6J mice; CDCA (sigma); Gibco DMEM medium; NP40 lysis buffer; protease inhibitors; phosphatase inhibitors; Yazyme gel rapid preparation kit.

[0086] Experimental steps:

[0087] 1. Isolate primary bone marrow cells from healthy C57BL / 6J mice, prepare single cell suspension through filtration, add 20ng / ml cytokines GM-CSF and IL-6 for culture after red cell lysis, supplement cytokines and change medium on the 2nd and 4th days.

[0088] 2. On the 4th day, 50 μM CDCA was added and treated for 48 h; cells not treated with CDCA served as the control group.

[0089] 3. After the treatment, collect the samples, add NP40 lysis buffer containing protease inhibitors and phosphatase inhibitors, extract the total protein, perform polyacrylamide gel electrophoresis and transfer to the membrane, and incubate the samples with WB antibodies of Arg1 and NOS2 at 4°C overnight.

[0090] 4. Incubate the secondary antibody at room temperature for 1 hour and expose to light.

[0091] Experimental results:

[0092] The experimental results are as follows Figure 3 As shown, at the protein level, the function of N2 neutrophils was reversed after CDCA treatment. Compared with the control group, the expression level of Arg1 protein was decreased, and the expression level of NOS2 protein was significantly increased.

[0093] Example 4: Bile acid CDCA and others reversed the immunosuppressive effect of N2 neutrophils on T cells

[0094] Experimental materials and reagents: C57BL / 6J mice; CDCA (sigma); Biolegend CD8a + Biotin-labeled conjugated antibody; Miltenyi anti-biotin magnetic beads; Gibco DMEM medium; Gibco RPIM 1640 medium; CFSE fluorescent probe (Biyuntian); IL-2; IL-6; GM-CSF and other cytokines

[0095] Experimental steps:

[0096] 1. Isolate primary cells from the bone marrow of healthy C57BL / 6J mice, add GM-CSF and IL-6 cytokines and culture for 4 days. Supplement cytokines and change medium on the 2nd and 4th days.

[0097] 2. On the 4th day, the medium was replaced and 50 μM CDCA was added for 48 h; cells not treated with CDCA served as the control group.

[0098] 3. Isolation of CD8 from Mouse Spleens +T cells were stained with CFSE, and CDCA-treated N2 neutrophils were co-incubated with CFSE-labeled T cells.

[0099] 4. After 48 hours of co-incubation, cell proliferation was detected by flow cytometry.

[0100] Experimental results:

[0101] The experimental results are as follows Figure 4 As shown, CDCA reversed the immunosuppressive effect of N2 neutrophils on T cells.

[0102] Example 5: Controlling tumor growth through bile acid CDCA metabolism regulation

[0103] Experimental materials and reagents:

[0104] C57BL / 6J tumor-bearing mice (melanoma B16).

[0105] Experimental steps:

[0106] 1. C57BL / 6J mice were subcutaneously loaded with B16 tumor.

[0107] 2. CDCA treatment (20 mg / kg) was started in drinking water on the 10th day of tumor bearing. 3 The mice were killed and the tumors were removed and photographed; tumor-bearing mice without CDCA treatment served as the control group; the experiment was repeated 6 times.

[0108] Experimental results:

[0109] The experimental results are as follows Figure 5 As shown, CDCA administration had an inhibitory effect on tumor growth.

[0110] Example 6: Increasing N1 neutrophils and reducing N2 neutrophils in the tumor microenvironment through bile acid CDCA metabolism regulation

[0111] Experimental materials and reagents:

[0112] C57BL / 6J mice, CDCA (sigma), Biolegend CD11b + Biotin-labeled conjugated antibody, Ly6G, Ly6c flow cytometry antibodies, Miltenyi anti-biotin magnetic beads, Sigma collagenase, hyaluronidase, DNase.

[0113] Experimental steps:

[0114] C57BL / 6J mice were subcutaneously loaded with B16 tumors and treated with CDCA (20 mg / kg) in drinking water starting on the 10th day of tumor bearing. Tumor-bearing mice without CDCA treatment served as the control group. When the tumor size exceeded 2000 mm 3 The mice were killed and the tumors were removed. The tumor tissues were cut into pieces and digested with collagenase, DNase, and hyaluronidase at 37°C for 2 hours. After digestion, the tumor tissues were ground and filtered through gauze to prepare single-cell suspension. Centrifuged at a low speed of 400 rpm for 3 times, 5 minutes each time, to remove most of the tumor cells. For surface antigen antibody staining, keep on ice for 30 minutes, add 500 μl flow buffer (PBS containing 2% serum) to neutralize the antibodies and centrifuge, resuspend in 200 μl flow buffer and load on the machine for flow cytometry detection.

[0115] Experimental results:

[0116] The experimental results are as follows Figure 6 As shown, N1 neutrophils (Ly6c + 6G + ) have increased significantly in both proportion and number.

[0117] Example 7: Reversing the function of N2 neutrophils through bile acid CDCA metabolism regulation, reducing immunosuppression, and enhancing the anti-tumor function of other cells such as T cells through cell interactions

[0118] Experimental materials and reagents:

[0119] C57BL / 6J mice, CDCA (sigma), Biolegend CD11b + Biotin-labeled conjugated antibody, CD4, CD8 flow cytometry antibodies, Miltenyi anti-biotin magnetic beads, Sigma collagenase, hyaluronidase, DNase.

[0120] Experimental steps:

[0121] C57BL / 6J mice were subcutaneously loaded with B16 tumors and treated with CDCA (20 mg / kg) in drinking water starting on the 10th day of tumor bearing. Tumor-bearing mice without CDCA treatment served as the control group. When the tumor size exceeded 2000 mm 3The mice were killed and the tumors were removed. The tumor tissues were cut into pieces and digested with collagenase, DNase, and hyaluronidase at 37°C for 2 hours. After digestion, the tumor tissues were ground and filtered through gauze to prepare single-cell suspension. Centrifuged at a low speed of 400 rpm for 3 times, 5 minutes each time, to remove most of the tumor cells. For surface antigen antibody staining, keep on ice for 30 minutes, add 500 μl flow buffer (PBS containing 2% serum) to neutralize the antibodies and centrifuge, resuspend in 200 μl flow buffer and load on the machine for flow cytometry detection.

[0122] Experimental results:

[0123] The experimental results are as follows Figure 7 As shown, CD8 + The proportion and number of T cells increased significantly.

[0124] Example 8: Controlling tumor growth in mice by administration of bile acids

[0125] Experimental materials and reagents:

[0126] C57BL / 6J tumor-bearing mice (mouse colon cancer cell MC38).

[0127] Experimental steps:

[0128] 1. C57BL / 6J mice were subcutaneously tumor-bearing MC38.

[0129] 2. CDCA, DCA, and OCA were administered in drinking water (20 mg / kg, DMSO as solvent) on the 10th day of tumor bearing. 3 The mice were killed and the tumors were removed and photographed; the tumor-bearing mice with an equal amount of DMSO added to their drinking water served as the control group; the experiment was repeated 7 times.

[0130] Experimental results:

[0131] The experimental results are as follows Figure 8 As shown, bile acid administration had an inhibitory effect on tumor growth.

Claims

1. A method for reversing the function of N2 neutrophils, characterized in that: The method comprises the step of adding bile acid to N2 neutrophils.

2. The method according to claim 1, characterized in that: The bile acid includes one or more of chenodeoxycholic acid, cholic acid, deoxycholic acid, lithocholic acid and 6-ethylchenodeoxycholic acid.

3. The method according to claim 1 or 2, characterized in that: Prior to the step of adding bile acid to N2 type neutrophils, the method further comprises a step of inducing N2 type neutrophils in vitro.

4. The method according to any one of claims 1 to 3, characterized in that In the step of adding bile acid to the N2 type neutrophils, the amount of bile acid added is such that the growth environment of the N2 type neutrophils contains 40 to 60 μM bile acid.

5. The method according to any one of claims 1 to 4, characterized in that: The reversal of the function of N2 neutrophils includes any one or more of the following (i) to (iii): (i) Reduce or eliminate the ability of N2 neutrophils to secrete immunosuppressive factors; (ii) enabling N2 neutrophils to produce or enhance their ability to secrete immune-promoting factors; (iii) Reduce or eliminate the ability of N2 neutrophils to inhibit lymphocyte proliferation.

6. The method according to claim 5, characterized in that The immunosuppressive factors include one or more of IL-10, TGF-β and arginase, the immunopromoting factors include one or more of NOS2, NOX2 and IFN-γ, and the lymphocytes include T cells and NK cells.

7. A functionally reversed N2 neutrophil, characterized in that: The function-reversed N2 neutrophils are prepared by the method according to any one of claims 1 to 6.

8. The function-reversed N2 neutrophil according to claim 7, characterized in that: The functions of the functionally reversed N2 neutrophils include any one or more of the following (i) to (iii): (i) reduced or absent ability to secrete immunosuppressive molecules; (ii) the ability to produce or enhance the secretion of immune-promoting factors; (iii) Reduced or absent ability to inhibit lymphocyte proliferation.

9. The function-reversed N2 neutrophil according to claim 8, characterized in that: The immunosuppressive factors include one or more of IL-10, TGF-β and arginase, the immunopromoting factors include one or more of NOS2, NOX2 and IFN-γ, and the lymphocytes include T cells and NK cells.

10. Use of the functionally reversed N2 neutrophils according to any one of claims 7 to 9 in the preparation of a drug for preventing and / or treating tumors; Optionally, the tumor includes any one or more of liver cancer, lung cancer, pancreatic cancer, kidney cancer, gastric cancer, esophageal cancer, colon cancer, bladder cancer, breast cancer, ovarian cancer, cervical cancer, renal clear cell carcinoma, melanoma, fibroma and nasopharyngeal carcinoma.